ReviewFrontiers in oncology2021

Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering.

Yishan Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.